上海之江生物科技股份有限公司 2025 年第二次临时股东会会议资料 证券代码：688317 证券简称：之江生物 | 2025 | 年第二次临时股东会会议须知 3 | | --- | --- | | 2025 | 年第二次临时股东会会议议程 5 | | 2025 | 年第二次临时股东会会议议案 6 | | | 议案一：《关于开展外汇衍生品交易业务的议案》 6 | 2 上海之江生物科技股份有限公司 2025 年第二次临时股东会会议资料 2025 年 11 月 1 上海之江生物科技股份有限公司 2025 年第二次临时股东会会议资料 上海之江生物科技股份有限公司 2025 年第二次临时股东会会议资料目录 上海之江生物科技股份有限公司 2025 年第二次临时股东会会议资料 上海之江生物科技股份有限公司 2025 年第二次临时股东会会议须知 二、为保证本次股东会的严肃性和正常秩序，切实维护股东的合法权益，请 出席股东会的股东或其代理人或其他出席者在会议召开前半小时到达会场签到 确认参会资格。 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证大 会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券 ...

Core Points - Shanghai Zhijiang Biological Technology Co., Ltd. has recently obtained a Class III medical device registration certificate for one of its products, enhancing its product offerings and overall competitiveness in the market [1] Group 1: Medical Device Registration - The company has received a registration certificate for a product that utilizes mature fluorescence PCR technology and lyophilization processes, aimed at providing a precise and convenient testing tool for clinical use [1] Group 2: Impact on the Company - The approval of the new product enriches the company's existing product range and strengthens its comprehensive competitiveness in the industry [1] Group 3: Share Buyback Announcement - On October 15, 2025, the company approved a share buyback plan, intending to repurchase shares using its own funds and a special loan for stock buybacks, with a total amount between RMB 60 million and RMB 120 million [7] - The buyback price is set at a maximum of RMB 37.99 per share, with a buyback period of 12 months from the board's approval date [7] - As of October 31, 2025, the company had not yet implemented the share buyback, but on November 3, 2025, it repurchased 92,000 shares at a total cost of RMB 2.0881 million, representing 0.05% of the total share capital [8]

Core Points - Zhijiang Biology announced that as of October 31, 2025, the company has not yet implemented any share buybacks [1] Company Summary - The announcement indicates that Zhijiang Biology is currently not engaging in share repurchase activities, which may reflect its strategic focus or financial position [1]

Core Viewpoint - Zhijiang Biotech (688317.SH) has recently obtained a Class III medical device registration certificate for its product, the novel coronavirus 2019-nCoV nucleic acid test kit (fluorescent PCR method) [1] Group 1 - The product is specifically designed for the detection of the novel coronavirus [1] - The registration certificate indicates compliance with national medical device regulations, enhancing the company's product portfolio [1] - This development may position the company favorably in the healthcare market, particularly in the context of ongoing pandemic responses [1]

Core Viewpoint - Zhijiang Biology (688317.SH) announced its first share buyback on November 3, 2025, through the Shanghai Stock Exchange, indicating a strategic move to enhance shareholder value [1] Summary by Categories Share Buyback Details - The company repurchased 92,000 shares, which represents 0.05% of its total share capital of 192 million shares [1] - The highest price for the repurchased shares was 22.86 CNY per share, while the lowest price was 22.56 CNY per share [1] - The total amount spent on the buyback was 2.0881 million CNY, excluding transaction fees such as stamp duty and commissions [1]

Core Viewpoint - Zhijiang Biotech (688317.SH) has recently obtained a Class III medical device registration certificate for its product, the novel coronavirus 2019-nCoV nucleic acid detection kit (fluorescent PCR method) [1] Group 1 - The product is specifically designed for the detection of the novel coronavirus [1] - The registration certificate indicates compliance with national medical device regulations, enhancing the company's product portfolio [1]

证券代码：688317 证券简称：之江生物 公告编号：2025-063 上海之江生物科技股份有限公司 2025 年 11 月 3 日，公司通过上海证券交易所交易系统以集中竞价交易方式首 次回购公司股份 92,000 股，占公司总股本 192,157,999 股的比例为 0.05%，回购 成交的最高价为 22.86 元/股，最低价为 22.56 元/股，支付的资金总额为人民币 208.81 万元（不含印花税、交易佣金等交易费用）。 关于 2025 年第三次以集中竞价交易方式首次回购股份 暨回购进展公告 2025 年 10 月 15 日，上海之江生物科技股份有限公司（以下简称"公司"）召 开第五届董事会第十六次会议，审议通过了《关于以集中竞价交易方式回购公司 股份方案的议案》，同意公司以自有资金和股票回购专项贷款资金通过集中竞价交 易方式回购公司部分股份，回购的股份拟用于员工持股计划或股权激励，回购股 份价格不超过人民币 37.99 元/股（含），回购资金总额不低于人民币 6,000 万元 （含），不超过人民币 12,000 万元（含），回购期限自公司董事会审议通过本次回 购方案之日起 12 个月内。具体内容详见 ...

证券代码：688317 证券简称：之江生物 公告编号：2025-062 上海之江生物科技股份有限公司 关于自愿披露公司产品获得相关认证的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海之江生物科技股份有限公司（以下简称"公司"）1 项产品于近期获得 国家三类医疗器械注册证，现将具体情况公告如下： 一、医疗器械注册证具体情况 | 注 | 册 | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 产品名称 | 证书编号 | 注册证有效期 | 适用范围 | 分 | | | | | | | | | | | 类 | 新型冠状病毒 | 2019-nCoV | 2025 | 年 | 10 | 月 | 27 | 新 | 型 | 冠 | 状 | 病 | 毒 | | 国 | 械 | 注 | 准 | 核酸检测试剂盒（荧光 | PCR | 日至 | 2030 | 年 ...

Core Viewpoint - The company has recently obtained a Class III medical device registration certificate for a new product, which is a nucleic acid detection kit for the novel coronavirus 2019-nCoV, indicating a significant advancement in its product offerings and potential market impact [1] Group 1: Product Details - The product is named "Nucleic Acid Detection Kit for Novel Coronavirus 2019-nCoV (Fluorescent PCR Method)" [1] - The registration certificate number is 20253402166, with a validity period from October 27, 2025, to October 26, 2030 [1] - The product utilizes mature fluorescent PCR technology and lyophilization processes, aimed at providing a precise and convenient detection tool for clinical use [1]

证券代码：688317 证券简称：之江生物 公告编号：2025-060 上海之江生物科技股份有限公司 关于 2025 年前三季度转回资产减值准备的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年 10 月 28 日，上海之江生物科技股份有限公司（以下简称"公司"） 召开第五届董事会第十七次会议，审议通过了《关于 2025 年前三季度转回资产 减值准备的议案》，该议案无需提交公司股东会审议，现将具体事宜公告如下： 一、转回资产减值准备情况概述 根据《企业会计准则》和公司会计政策、会计估计的相关规定，为客观、公 允地反映公司 2025 年 9 月 30 日的财务状况和 2025 年前三季度的经营成果，公 司及下属子公司对截至 2025 年 9 月 30 日的公司资产进行了充分的评估和分析， 本着谨慎性原则，公司对相关资产进行了全面清查和减值测试。经测算，2025 年前三季度公司转回减值损失共计 16,497,013.80 元，具体情况如下： 单位：人民币元 | | | | 项目 | 前三季度转回金额 | | - ...